lcmv gp-33-41

LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an H-2Db restricted epitope derived from the lymphocytic choriomeningitis virus (LCMV) glycoprotein gp 33 (residues 33 to 41) and is presented to cytotoxic T lymphocytes by MHC class I H-2Db molecules.

LCMV gp33-41 acetate is a sequence of lymphocytic choriomeningitis virus which restricted by major histocompatibility complex class I H-2Db and presented to cytotoxic T lymphocytes.

LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].

LCMV gp33-41 (TFA), an 11-amino-acid carboxyl-extended peptide, comprises a lymphocytic choriomeningitis virus sequence that is presented by MHC class I H-2Db molecules to cytotoxic T lymphocytes [1].

GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM. GP(33-41) Epitope is a strong agonist of CD8 T cells from P14 TCR-transgenic mice.

LCMV GP (61-80) is a peptide fragment from LCMV glycoprotein (GP), corresponding to amino acids 61-80, and it can elicit a CD4+ T-cell response.

GP(33-41) TFA, a 9-amino-acid (aa) peptide, represents the optimal sequence of the lymphocytic choriomeningitis virus GP1 epitope, effectively upregulating H-2D b molecules on the RMA-S (Db Kb) cell surface with an SC50 value of 344 nM [1].